Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Am J Transplant. 2015 Dec 11;16(3):938–950. doi: 10.1111/ajt.13542

Figure 3. Serum sST2 is increased during HTx rejection and decreases following recipient treatment.

Figure 3

Circulating sST2 was assessed by ELISA in HTx recipient serum samples obtained serially in the first year post-transplant. (A) Changes of sST2 concentrations are depicted for all patients grouped into cohorts based on Year 1 (Y1) outcomes. Groups include patients suffering one or more episodes of diagnosed ACR (Grade≥2R) and/or histologically and C4d+ indicated pathogenic AMR, or those remaining free from ACR or AMR during Y1 (No Rejection; NoR). (B) Panels depict individual recipients representative of the indicated group. Black arrows indicate times of recipient treatment for rejection; d = points of graft dysfunction; All EMB grades over 0 indicated at appropriate time point. ACR, acute cellular rejection; AMR, antibody-mediated rejection; HTx, heart transplant; sST2, soluble ST2.